![]() FDA requests removal of Opana® ER for risks related to abuse. Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will continue providing coverage of OPANA ER claims for our members until stock is depleted from all pharmacies.ġ FDA News Release. Please discuss alternative medications with your patients. The company plans to work with the FDA to coordinate the orderly removal of OPANA ER in a way that minimizes treatment disruption for patients and allows patients sufficient time to seek guidance from their healthcare professionals. Food and Drug Administration (FDA) requesting that. voluntarily removed OPANA ER from the market on July 6, 2017. DUBLIN, J/PRNewswire/ - Endo International plc (NASDAQ: ENDP) is aware of todays announcement by the U.S. 1įollowing the FDA’s request, Endo Pharmaceuticals, Inc. Aug 16 (Reuters) - Endo International Plc (ENDP.O) filed for bankruptcy on Tuesday after reaching a 6 billion deal with some of its creditors, as the U.S. Injection abuse of the drug has been associated with a serious outbreak of HIV and hepatitis C, as well as cases of a serious blood disorder (thrombotic microangiopathy). The FDA’s review of all available post-marketing data demonstrated a significant shift in the route of abuse following the product’s reformulation from nasal to injection. The FDA sought removal based on its concern that the benefits of the drug may no longer outweigh its risks. remove its opioid pain medication, reformulated OPANA ® ER (oxymorphone hydrochloride) from the market. ![]() On June 8, 2017, the US Food and Drug Administration (FDA) requested that Endo Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |